Literature DB >> 27925423

The Johns Hopkins Venous Thromboembolism Collaborative: Multidisciplinary team approach to achieve perfect prophylaxis.

Michael B Streiff1,2,3, Brandyn D Lau3,4,5,6, Deborah B Hobson3,4,7, Peggy S Kraus8, Kenneth M Shermock1,8,9, Dauryne L Shaffer4,7, Victor O Popoola4, Jonathan K Aboagye4, Norma A Farrow4, Paula J Horn10, Hasan M Shihab4, Peter J Pronovost3,6,11,12, Elliott R Haut3,4,6,11,13.   

Abstract

Venous thromboembolism (VTE) is an important cause of preventable harm in hospitalized patients. The critical steps in delivery of optimal VTE prevention care include (1) assessment of VTE and bleeding risk for each patient, (2) prescription of risk-appropriate VTE prophylaxis, (3) administration of risk-appropriate VTE prophylaxis in a patient-centered manner, and (4) continuously monitoring outcomes to identify new opportunities for learning and performance improvement. To ensure that every hospitalized patient receives VTE prophylaxis consistent with their individual risk level and personal care preferences, we organized a multidisciplinary task force, the Johns Hopkins VTE Collaborative. To achieve the goal of perfect prophylaxis for every patient, we developed evidence-based, specialty-specific computerized clinical decision support VTE prophylaxis order sets that assist providers in ordering risk-appropriate VTE prevention. We developed novel strategies to improve provider VTE prevention ordering practices including face-to-face performance reviews, pay for performance, and provider VTE scorecards. When we discovered that prescription of risk-appropriate VTE prophylaxis does not ensure its administration, our multidisciplinary research team conducted in-depth surveys of patients, nurses, and physicians to design a multidisciplinary patient-centered educational intervention to eliminate missed doses of pharmacologic VTE prophylaxis that has been funded by the Patient Centered Outcomes Research Institute. We expect that the studies currently underway will bring us closer to the goal of perfect VTE prevention care for every patient. Our learning journey to eliminate harm from VTE can be applied to other types of harm. Journal of Hospital Medicine 2016;11:S8-S14.
© 2016 Society of Hospital Medicine. © 2016 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27925423     DOI: 10.1002/jhm.2657

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  11 in total

Review 1.  Advances in Clinical Decision Support: Highlights of Practice and the Literature 2015-2016.

Authors:  R A Jenders
Journal:  Yearb Med Inform       Date:  2017-09-11

2.  Low anti-Factor Xa level predicts 90-day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis: A Pooled Analysis of Eight Clinical Trials.

Authors:  Christopher J Pannucci; Kory I Fleming; Thomas K Varghese; John Stringham; Lyen C Huang; T Bartley Pickron; Ann Marie Prazak; Corinne Bertolaccini; Arash Momeni
Journal:  Ann Surg       Date:  2020-10-19       Impact factor: 12.969

3.  Electronic health record risk-stratification tool reduces venous thromboembolism events in surgical patients.

Authors:  Radhika Rastogi; Courtney M Lattimore; J Hunter Mehaffey; Florence E Turrentine; Hillary S Maitland; Victor M Zaydfudim
Journal:  Surg Open Sci       Date:  2022-04-26

4.  Missed Doses of Venous Thromboembolism Prophylaxis: a Growing Problem Without an Active Management Strategy.

Authors:  Brandyn D Lau; Jiangxia Wang; Deborah B Hobson; Peggy S Kraus; Dauryne L Shaffer; Michael B Streiff; Elliott R Haut
Journal:  J Gen Intern Med       Date:  2020-11-02       Impact factor: 5.128

5.  Monitoring intensive care unit performance-impact of a novel individualised performance scorecard in critical care medicine: a mixed-methods study protocol.

Authors:  Shannon M Fernando; David Neilipovitz; Aimee J Sarti; Erin Rosenberg; Rabia Ishaq; Mary Thornton; John Kim
Journal:  BMJ Open       Date:  2018-01-21       Impact factor: 2.692

6.  Multidisciplinary, patient-centred approach to improving compliance with venous thromboembolism (VTE) prophylaxis in a district general hospital.

Authors:  Melanie Nana; Cherry Shute; Rhys Williams; Flora Kokwaro; Kathleen Riddick; Helen Lane
Journal:  BMJ Open Qual       Date:  2020-07

7.  Using knowledge translation for quality improvement: an interprofessional education intervention to improve thromboprophylaxis among medical inpatients.

Authors:  Melissa K Myers; Claire L Jansson-Knodell; Darrell R Schroeder; John G O'Meara; Sara L Bonnes; John T Ratelle
Journal:  J Multidiscip Healthc       Date:  2018-09-18

8.  Effect of Real-time Patient-Centered Education Bundle on Administration of Venous Thromboembolism Prevention in Hospitalized Patients.

Authors:  Elliott R Haut; Jonathan K Aboagye; Dauryne L Shaffer; Jiangxia Wang; Deborah B Hobson; Gayane Yenokyan; Elizabeth A Sugar; Peggy S Kraus; Norma E Farrow; Joseph K Canner; Oluwafemi P Owodunni; Katherine L Florecki; Kristen L W Webster; Christine G Holzmueller; Peter J Pronovost; Michael B Streiff; Brandyn D Lau
Journal:  JAMA Netw Open       Date:  2018-11-02

9.  Impact of a Program to Improve Venous Thromboembolism Prophylaxis on Incidence of Thromboembolism and Bleeding Rates in Hospitalized Patients During Implementation of Programs to Improve Venous Thromboembolism Prophylaxis.

Authors:  Jenna K Lovely; Joel A Hickman; Matthew G Johnson; James M Naessens; Timothy I Morgenthaler
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2020-02-17

10.  Using electronic health record system triggers to target delivery of a patient-centered intervention to improve venous thromboembolism prevention for hospitalized patients: Is there a differential effect by race?

Authors:  Oluwafemi P Owodunni; Elliott R Haut; Dauryne L Shaffer; Deborah B Hobson; Jiangxia Wang; Gayane Yenokyan; Peggy S Kraus; Jonathan K Aboagye; Katherine L Florecki; Kristen L W Webster; Christine G Holzmueller; Michael B Streiff; Brandyn D Lau
Journal:  PLoS One       Date:  2020-01-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.